Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene to pay $2.9bn to acquire Abraxis BioScience

Executive Summary

Publicly traded Abraxis BioScience Inc. (nanoparticle-based cancer drugs) has agreed to be acquired by Celgene Corp. for $2.9bn. For each of its company's shares held, Abraxis stockholders will receive $58 in cash and 0.2617 Celgene shares, or about $72 per share (a 17% premium).
Deal Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Intra-Biotech Deal
    • Includes Earnout
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register